Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.
Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.